Abstract YO39
Case summary
Background: Follicular thyroid carcinoma commonly presents with hematogenous metastasis to the lung and bone and rarely to the kidney. We report a case of a 61-year old woman with a metastatic follicular thyroid carcinoma to the kidney. This case report shows how a systematic approach on a patient with a renal mass can lead to a diagnosis of an unexpected primary cancer.
Case Report: A 61-year old female presented with progressively enlarging back mass. Whole abdominal ultrasound revealed right renal mass; chest CT scan showed multiple heterogeneously varisized pulmonary nodules. Ct-guided fine needle aspiration biopsy of the lung nodule was compatible with a non-small cell carcinoma. Immuno-histochemistry was positive for CK7, TTF1 and thyroglobulin and CK 20 negative favoring metastatic thyroid carcinoma. Ultrasound-guided core needle biopsy of the renal mass was compatible with thyroid carcinoma, metastatic (thyroglobulin positive). The final histopathology report after thyroidectomy was non-invasive follicular thyroid neoplasm with papillary-like nuclear features. The patient received radioactive iodine and is now with better quality of life.
Discussion: Metastatic follicular thyroid carcinoma is a rare phenomenon with only 25 cases reported in the English literature to date. Johnson et al in 1982 reported a case of follicular thyroid carcinoma with metastasis to the kidney 37 years after resection of the primary tumor. In a study by Parameswaran in 2016 on patterns of metastasis in follicular thyroid carcinoma, they found out that 40% of cases metastasized at a median of 4.5 years after initial thyroidectomy, lungs being the most common site followed by bone (25%), regional lymph nodes (13%) and brain (12%). None of the said cohort had metastasis to the kidney. The best management of FTC presenting as metastatic disease should be managed aggressively with total thyroidectomy followed by RAI which was done in our patient.
Conclusion: Given the rarity of thyroid metastasis to the kidney, a diagnostic dilemma for this case was a challenge. This case provides new data to clinicians that thyroid carcinoma can metastasize to the kidney and may mimic renal cell carcinoma although rarely reported.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract